阿德福韦酯联合胸腺五肽治疗HBeAg阳性慢性乙型肝炎的疗效观察

目的观察阿德福韦酯联合胸腺五肽治疗慢性乙型肝炎抗乙肝病毒的效果。方法将46例HBeAg阳性慢性乙型病毒性肝炎患者随机分为阿德福韦酯组和联合治疗组，阿德福韦酯组24例，口服阿德福韦酯10mg／d；联合治疗纽22例，阿德福韦酯（10mg／d）联合胸腺五肽（1mg皮下注射，每周3次）治疗，24周后单服阿德福韦酯，两组疗程均为48周。结果在治疗24周时，联合治疗组的HBVDNA阴转率、HBeAg的阴转率和HBeAg／HBeAb的血清转换率显著高于对照组。在治疗24、48周时，两组丙氨酸氨基转移酶复常率比较差异无统计学意义（P〉0．05）。48周时，两组HBeAg的阴转率和HBeAg／HBeAb的血清转换率比较差异有统计学意义（P〈0．05）。结论阿德福韦酯与胸腺五肽联合治疗HBeAg阳性慢性乙型肝炎，能够显著提高HBeAg的阴转率和HBeAg／HBeAb的血清转换率。

Clinical research on adefovir dipivoxii combined with thymopentin in the treatment of hepatitis Be antigen positive chronic hepatitis B

Objective To explore the efficacy of adefovir dipivoxil combined with thymopentin in the treatment of chronic hepatitis B. Methods Forty - six patients with hepatitis Be antigen positive chronic hepatitis B were randomly divided into adefovir dipivoxil group and combination group. 24 pa- tients （adefovir dipivoxil group） were treated with adefovir dipivoxil 10 mg/d alone ;22 patients （combi- nation group） were treated with combination therapy：after treatment with Adefovir dipivoxil and Thymopentin that was applied with 1 mg intramuscularly per day, third a week for 24 weeks,combined with the treatment of adefovir dipivoxil, all for 48 weeks. Results After 24 weeks, the rate of HBV DNA under detection, HBeAg loss and HBeAg seroconversion rates in combinaiton group were also higher that in adefovir dipivoxil group. The normalization rates of ALT in adefovir dipivoxil group and eombinaiton group after 24 weeks and 48 weeks had no difference. After 48 weeks, there were significant difference be- tween adefovir dipivoxil group and combinaiton group such as HBeAg loss and HBeAg seroconversion rates. Conclusions The negative conversion rate of HBV DNA, HBeAg negative rate and HBeAg/HBeAb lipid negative can be remarkabl increased in adefovir dipivoxil combined with thymopentin group.